Show simple item record

dc.contributor.authorDirector, Moderna Medical
dc.description.abstractThe clinical study will assess the safety, tolerability, and immunogenicity of mRNA-1325 in healthy adult subjects. Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Participant, Investigator Primary Purpose: Prevention Official Title: A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Regionen_US
dc.subjectZika Research Projecten_US
dc.subjectZika Virusen_US
dc.subjectUnited Statesen_US
dc.titleSafety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjectsen_US
eihealth.categoryEpidemiology and epidemiological studiesen_US
eihealth.typeOther publicationsen_US
eihealth.maincategoryProtect Health Care Workers / Proteger la Salud de los Trabajadoresen_US
dc.relation.ispartofjournalClinical Trialsen_US
dc.contributor.corporatenameModerna Therapeutics, Biomedical Advanced Research and Development Authorityen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record